Universal Health International Group Holding Valuation
Is 2211 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 2211 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 2211's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 2211's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2211?
Key metric: As 2211 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 2211's PS Ratio? | |
|---|---|
| PS Ratio | 0.07x |
| Sales | CN¥1.09b |
| Market Cap | CN¥79.04m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.1x |
| Enterprise Value/EBITDA | -11.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 2211's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.8x | ||
8372 Grand Brilliance Group Holdings | 0.9x | n/a | HK$74.4m |
574 Pa Shun International Holdings | 0.6x | n/a | HK$63.4m |
401 Wanjia Group Holdings | 0.2x | n/a | HK$39.2m |
718 Tai United Holdings | 1.3x | n/a | HK$225.8m |
2211 Universal Health International Group Holding | 0.07x | n/a | HK$84.9m |
Price-To-Sales vs Peers: 2211 is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (0.8x).
Price to Sales Ratio vs Industry
How does 2211's PS Ratio compare vs other companies in the HK Healthcare Industry?
| 11 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 0.9x | 10.4% | |
2211 Universal Health International Group Holding | 0.07x | n/a | US$10.91m |
1099 Sinopharm Group | 0.1x | 5.8% | US$8.04b |
9885 YSB | 0.2x | n/a | US$505.51m |
| 11 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 0.9x | 18.5% | |
2211 Universal Health International Group Holding | 0.07x | n/a | US$10.91m |
Price-To-Sales vs Industry: 2211 is good value based on its Price-To-Sales Ratio (0.1x) compared to the Hong Kong Healthcare industry average (0.9x).
Price to Sales Ratio vs Fair Ratio
What is 2211's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.07x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 2211's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Sinopharm Group
HK$62.6b
Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.
1099
HK$20.05
7D
-0.7%
1Y
0.3%
OrbusNeich Medical Group Holdings
HK$3.4b
An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.
6929
HK$4.10
7D
-5.7%
1Y
-48.6%
Hygeia Healthcare Holdings
HK$10.2b
Offers oncology healthcare services in the People's Republic of China.
6078
HK$16.40
7D
-6.6%
1Y
-66.9%